Clinical trials
Hepatitis clinical trials
Below are recruiting hepatitis clinical trials, each written for real people, not researchers. We’re tracking 480 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05769816RecruitingPhase 2
Combination treatment aimed to cure chronic hepatitis B
This Phase 2 study tests a combination therapy to help people with chronic hepatitis B reach a “functional cure,” meaning the hepatitis B surface antigen (HBsAg) is lost for a sustained period. If you qualify, you’ll be closely monitored to see how well the treatment works and whether it’s safe for you.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT05771402RecruitingPhase 2
Combination treatment aimed at clearing hepatitis B long-term
This Phase 2 study tests a combination treatment to help people with chronic hepatitis B stop having detectable hepatitis B surface antigen (called HBsAg). If successful, it may move you closer to a “functional cure,” meaning lower ongoing virus activity over time.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT05492565Enrolling by invitation
Follow-up study for people on HIV prevention pills
This study follows adults who are at high risk of getting HIV while they take HIV prevention pills (PrEP). It aims to learn how well PrEP fits real-life use in people at risk and who may need extra care.
Seville, AndalusiaAges 18 years+ - NCT05433948Enrolling by invitation
Testing ways to diagnose mild brain changes in liver disease
This study looks at how well simple brain tests can detect early (minimal) thinking changes related to liver cirrhosis. It may help doctors spot these changes sooner and diagnose the condition more accurately.
EsbjergAges 18–90 - NCT05345847Recruiting
Steroid-sparing treatment for immune hepatitis during cancer immunotherapy
This trial studies a way to treat inflammation of the liver (hepatitis) caused by immune cancer medicines (anti-PD-1/PD-L1, sometimes with anti-CTLA-4) without relying on high-dose steroids. It may help reduce steroid side effects while keeping liver inflammation under control.
Calgary, AlbertaAges 18 years+ - NCT05286814RecruitingPhase 2
Pump-delivered therapy plus chemo for liver-metastatic cancers
This phase 2 study tests a liver-targeted medicine delivered through a special implanted pump, combined with standard chemo, for cancers that spread mainly to the liver. It may help control tumor growth in the liver and improve outcomes compared with standard treatment alone.
Bethesda, MarylandAges 18–120 - NCT05248919Enrolling by invitation
Study treatment for hepatitis C that did not work before
This trial looks at hepatitis C treatment for people whose last antiviral medicines did not fully clear the virus. It may help by testing a study drug approach for people in Pakistan who still have active hepatitis C infection.
Karachi, SindhAges 18–100 - NCT05045482RecruitingPhase 1
Study drug in people with cirrhosis from blocked bile flow
This Phase 1 trial studies how saroglitazar magnesium works in people with liver scarring (cirrhosis) caused by a bile-flow problem. It helps doctors understand safety and how the body handles the medicine in this specific liver condition.
Indianapolis, IndianaAges 18–80 - NCT05027711RecruitingPhase 2
MRI-guided precise radiation for liver metastases
This Phase 2 trial tests an MRI-guided, highly targeted radiation treatment (SBRT) for tumors that have spread to the liver. It may help shrink 1–3 liver metastases while using imaging to better guide treatment.
HeidelbergAges 18 years+ - NCT05018481RecruitingEarly Phase 1
Study for moderate alcoholic hepatitis after heavy drinking
This early-phase study is testing a treatment approach for people with alcoholic hepatitis (liver inflammation caused by heavy alcohol use). It may help by improving liver function and outcomes in people who meet specific lab and health criteria.
Cleveland, OhioAges 21–65 - NCT05051098Recruiting
Registry for people with hepatitis B infection
This study is a registry, meaning it collects health information from people living with hepatitis B rather than giving a new treatment. It may help researchers better understand different hepatitis B groups and outcomes over time.
HanoverAges 18 years+ - NCT04914611Recruiting
Real-world study of chronic hepatitis B care in Australia
This study looks at people who have long-term hepatitis B and how they receive care in Australia. It may help improve understanding of what’s working in real life for patients like you.
Sydney, New South WalesAges 18 years+ - NCT04883905Recruiting
Registry study for people with acute hepatic porphyria
This study is a registry (a list) of people diagnosed with acute hepatic porphyria. It helps researchers learn about the condition and track health information over time; it doesn’t test a new drug in the way treatment trials do.
Birmingham, AlabamaAges 12 years+ - NCT04493385Recruiting
Heart transplant after a hepatitis C–positive donor
This trial follows people who receive a heart from a donor whose blood tested positive for hepatitis C. It also includes people getting a heart transplant again, and it aims to learn about outcomes and safety for these specific transplant situations.
Dallas, TexasAges 18 years+ - NCT04271488RecruitingPhase 1
Study drug levels in people with mild or moderate liver problems
This Phase 1 study measures how tasurgratinib (E7090) and its breakdown product move through the body in people with mild or moderate liver impairment. It aims to understand appropriate dosing and safety considerations for liver impairment.
Hakata, FukuokaAges 20–79 - NCT04234139Enrolling by invitation
Study of severe alcoholic hepatitis patients before early liver transplant
This study follows people with severe alcoholic hepatitis who are being considered for an early liver transplant before they’ve been sober for 6 months. It aims to better understand this group’s situation and ethics/safety as early transplantation plans are made.
Baltimore, MarylandAges 18 years+ - NCT04096014Recruiting
Protein supplement at night to prevent repeat brain episodes
This study tests whether taking extra protein in the late evening or early morning can lower the chance of being readmitted for hepatic encephalopathy, a brain problem that can happen with liver disease. It may help by supporting safer nutrition and reducing the risk of another hospitalization.
Cleveland, OhioAges 18–75 - NCT04088370Recruiting
Testing blood immune cell response in alcohol-related liver disease
This study looks at how immune cells in the blood respond in people with alcoholic hepatitis and in people who drink heavily (with no known liver disease). It may help researchers understand why liver inflammation happens after heavy alcohol use.
Cleveland, OhioAges 21–65 - NCT04106518Recruiting
Genetics study of alcohol-related liver disease and cirrhosis
This study looks at genetic differences in people with alcohol-related liver illness, including a recent jaundice episode (alcoholic hepatitis). By following people over time, it may help doctors better predict illness and understand why some people develop worse liver problems.
AngersAges 18 years+ - NCT03826433RecruitingPhase 1
Study stem cell treatment for worsening hepatitis B cirrhosis
This Phase 1 study tests a stem cell product to see if it is safe and how it affects people with worsening hepatitis B-related cirrhosis. It may help researchers understand whether the treatment could improve liver function in this stage of illness.
Changsha, HunanAges 18–60 - NCT03825458Recruiting
Study tracking hepatitis B viral RNA in blood
This study builds a group of people to measure small hepatitis B “viral RNA” signals in the blood. The goal is to see if these measurements could help researchers find a functional cure and better understand who may respond over time.
LyonAges 18 years+ - NCT03685045Recruiting
Hepatitis C treatment support for people using opioid substitutes
This trial is studying hepatitis C treatment approaches for adults who have a history of injecting drugs, especially those who have injected recently or are on opioid substitution therapy. If you fit the background criteria, the study may offer a treatment pathway and extra support to help you get hepatitis C treated.
Canberra, Australian Capital TerritoryAges 18 years+ - NCT03025074Recruiting
Blood sample bank for liver disease research
This study collects blood samples to build a “biobank” (a stored library of samples) for researchers studying liver diseases like hepatitis, fatty liver disease, and liver cancer. It may help future testing and treatments by allowing scientists to study patterns in people with and without liver conditions.
Buffalo, New YorkAges 7 years+ - NCT02699736Enrolling by invitation
HIV and hepatitis C study in European adults
This study follows people living with HIV who also have hepatitis C antibodies, to better understand how HIV and hepatitis C affect health over time. You may be able to join if you meet the age and enrollment requirements, even if your hepatitis C virus level is currently undetectable.
Buenos AiresAges 16 years+
Hear when a new Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatitis?
- Yes. Clin2 currently lists 480 recruiting hepatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.